BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Cynata Therapeutics Initiates Patient Treatment in World 1st Clinical Trial
cynata first patient CYP-001

Cynata Therapeutics Initiates Patient Treatment in World 1st Clinical Trial

May 29, 2017 By Cade Hildreth (CEO) Leave a Comment

In breaking news released earlier this month, Cynata Therapeutics (ASX: CYP) announced a major world first. The company treated a patient with steroid resistant acute graft-versus-host disease (GvHD) as part of a phase 1 clinical study of its first mesenchymal stem cell (MSC) product, CYP-001 .

Discover class-defining bioproduction tools.

This is an important value catalyst for Cynata and also for the regenerative medicine industry, because it is the first time ever that a patient has been treated with an allogeneic induced pluripotent stem cell (iPSC)-derived therapeutic mesenchymal stem cell (MSC) product.

Cynata Therapeutics Treats 1st Patient
The milestone also represents a giant leap forward in the production of MSCs, which is currently expensive, requires multiple extractions from different donors and relies on excessive expansion (division) of the cells to manufacture sufficient product. Cynata’s unique and proprietary Cymerus™ technology provides a completely different approach.

The Phase 1 clinical trial is expected to include a total of 16 patients who will receive two infusions of CYP-001, with a week between doses.

Rooster DevServices

According to Dr. Adrian Bloor, UK Chief Investigator in Cynata’s Phase 1 clinical trial in acute steroid resistant GvHD, the CymerusTM technology platform has the ability to create a stable clinical trial product using induced pluripotent stem cells sourced from a blood donation from a single donor. To date, MSC clinical trials have traditionally struggled with clinical endpoints and demonstrated variable results, because they rely on a massively expanded cellular product and require sourcing from multiple donors.

What would you like to know about Cynata’s Cymerus technology? Ask us in the comments below.

bitbio

Up Next: Cynata’s Cymerus™ Platform Technology – What is It, Exactly?

5/5 - (1 vote)

Filed Under: iPS Cells, Stem Cell News Tagged With: clinical trial, cynata therapeutics, GvHD, MSC

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

clean meat market

Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.